{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:07:28Z","timestamp":1790892448193,"version":"4.1.0"},"reference-count":228,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inflammatory bowel disease (IBD) is a multifactorial illness with a climbing prevalence worldwide. While biologics are commonly prescribed especially for severe cases, they may worsen patients\u2019 outcomes due to financial burden. Consequently, there has been an increased focus on biosimilars to improve overall disease outcomes by maintaining similar efficacy and safety while minimizing the cost of therapy. Infliximab-dyyb was the first biosimilar approved by US-FDA for IBD. Since that, the US-FDA approved 14 biosimilars with different mechanisms of action and different routes of administration for IBD patients (four infliximab biosimilars, nine adalimumab biosimilars, and most recently one ustekinumab biosimilar). It should be noted that more biologics are in the pipeline as golimumab and natalizumab patents are set to expire in the near future, and biosimilars are now in pre-clinical to phase 3 trials. Different studies have evaluated biologics' effectiveness and safety and concluded that the majority of available biosimilars are efficacious and have similar adverse effect profiles compared to their reference biologics. It is worth mentioningthat post-marketing surveillance reports revealed some risks associated with biosimilars which should be taken into consideration in future research and clinical trials to avoid health hazards. Most biologics and biosimilars are administered parenterally which results in several drawbacks such as raised risk of infections, hypersensitivity, autoimmunity, development of malignancies, liver toxicity as well as worsening of heart failure. Several drug delivery systems based on passive and active targeting mechanisms are under active investigation to overcome these limitations. This review sheds light on the emergence of biologics and biosimilars as alternatives in IBD management, the differences between them, challenges and risks, and future perspectives in IBD therapy and new trends in drug delivery systems.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s10238-025-01558-6","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:16:03Z","timestamp":1743891363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-9826","authenticated-orcid":false,"given":"Ahmed","family":"Aljabri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-1254","authenticated-orcid":false,"given":"Ghareb M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7374-9334","authenticated-orcid":false,"given":"Yasmin N.","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3866-2283","authenticated-orcid":false,"given":"Mohammed A.","family":"Medhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8541-7304","authenticated-orcid":false,"given":"Helal F.","family":"Hetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"issue":"1","key":"1558_CR1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10238-024-01476-z","volume":"24","author":"YN Ramadan","year":"2024","unstructured":"Ramadan YN, et al. MicroRNA signatures in the pathogenesis and therapy of inflammatory bowel disease. Clin Exp Med. 2024;24(1):217.","journal-title":"Clin Exp Med"},{"issue":"1","key":"1558_CR2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","volume":"94","author":"GP Ramos","year":"2019","unstructured":"Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc. 2019;94(1):155\u201365.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1558_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","volume":"16","author":"SH Lee","year":"2018","unstructured":"Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16(1):26\u201342.","journal-title":"Intest Res"},{"issue":"4","key":"1558_CR4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.autrev.2017.02.013","volume":"16","author":"JH Park","year":"2017","unstructured":"Park JH, et al. IBD immunopathogenesis: a comprehensive review of inflammatory molecules. Autoimmun Rev. 2017;16(4):416\u201326.","journal-title":"Autoimmun Rev"},{"issue":"10114","key":"1558_CR5","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769\u201378.","journal-title":"Lancet"},{"issue":"2","key":"1558_CR6","doi-asserted-by":"crossref","first-page":"92592","DOI":"10.5662\/wjm.v15.i2.92592","volume":"15","author":"HF Hetta","year":"2025","unstructured":"Hetta HF, Ramadan ARYN, Fathy H, Khorshid M, Mabrouk MM, Hashem M. Gut virome: New key players in the pathogenesis of inflammatory bowel disease. World J Methodol. 2025;15(2):92592.","journal-title":"World J Methodol"},{"issue":"3","key":"1558_CR7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/gastro\/gou031","volume":"2","author":"TC DeRoche","year":"2014","unstructured":"DeRoche TC, Xiao SY, Liu X. Histological evaluation in ulcerative colitis. Gastroenterol Rep. 2014;2(3):178\u201392.","journal-title":"Gastroenterol Rep"},{"issue":"4","key":"1558_CR8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1055\/s-2007-991030","volume":"20","author":"S Mills","year":"2007","unstructured":"Mills S, Stamos MJ. Colonic crohn\u2019s disease. Clin Colon Rectal Surg. 2007;20(4):309\u201313.","journal-title":"Clin Colon Rectal Surg"},{"issue":"7","key":"1558_CR9","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.mayocp.2017.04.010","volume":"92","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088\u2013103.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1558_CR10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1558_CR11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"GG Kaplan","year":"2021","unstructured":"Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1558_CR12","volume":"8","author":"X Guo","year":"2021","unstructured":"Guo X, et al. Gut microbiota is a potential biomarker in inflammatory bowel disease. Front Nutr. 2021;8: 818902.","journal-title":"Front Nutr"},{"issue":"12","key":"1558_CR13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/apt.15774","volume":"51","author":"S Papoutsopoulou","year":"2020","unstructured":"Papoutsopoulou S, et al. Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms. Aliment Pharmacol Ther. 2020;51(12):1268\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"1558_CR14","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.572912","volume":"10","author":"J Ramirez","year":"2020","unstructured":"Ramirez J, et al. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020;10: 572912.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"1558_CR15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/immuno4040026","volume":"4","author":"HF Hetta","year":"2024","unstructured":"Hetta HF, et al. Gut microbiome as a target of intervention in inflammatory bowel disease pathogenesis and therapy. Immuno. 2024;4(4):400\u201325.","journal-title":"Immuno"},{"issue":"1","key":"1558_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2019","unstructured":"Torres J, et al. ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment. J Crohn\u2019s Colitis. 2019;14(1):4\u201322.","journal-title":"J Crohn's Colitis"},{"issue":"1","key":"1558_CR17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2021","unstructured":"Raine T, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohn\u2019s Colitis. 2021;16(1):2\u201317.","journal-title":"J Crohn's Colitis"},{"key":"1558_CR18","doi-asserted-by":"crossref","first-page":"175628481986004","DOI":"10.1177\/1756284819860044","volume":"12","author":"M Santiago","year":"2019","unstructured":"Santiago M, et al. What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale. Therap Adv Gastroenterol. 2019;12:1756284819860044.","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"1558_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"1558_CR20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/1751-2980.12940","volume":"21","author":"S Talathi","year":"2020","unstructured":"Talathi S, Baig KRKK. Biosimilars in inflammatory bowel disease. J Dig Dis. 2020;21(11):610\u201320.","journal-title":"J Dig Dis"},{"issue":"3","key":"1558_CR21","doi-asserted-by":"crossref","first-page":"038","DOI":"10.1093\/crocol\/otab038","volume":"3","author":"R Panaccione","year":"2021","unstructured":"Panaccione R. The great debate with IBD biosimilars: con: biosimilars should not be routinely used as a first line biologic and not switched from reference biologics. Crohn\u2019s Colitis 360. 2021;3(3):038.","journal-title":"Crohn's Colitis 360"},{"key":"1558_CR22","unstructured":"Padda, I.S., et al., Biosimilars Use in Medicine for Inflammatory Diseases, in StatPearls. 2023, StatPearls Publishing"},{"key":"1558_CR23","unstructured":"Copyright \u00a9 2023, StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Rajat Bhatt declares no relevant financial relationships with ineligible companies. Disclosure: Obaid Rehman declares no relevant financial relationships with ineligible companies. Disclosure: Mayur Parmar declares no relevant financial relationships with ineligible companies."},{"issue":"7415","key":"1558_CR24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nature11550","volume":"489","author":"CA Lozupone","year":"2012","unstructured":"Lozupone CA, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220\u201330.","journal-title":"Nature"},{"issue":"2","key":"1558_CR25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ueg2.12357","volume":"11","author":"B Gros","year":"2023","unstructured":"Gros B, et al. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort. United European Gastroenterol J. 2023;11(2):179\u201388.","journal-title":"United European Gastroenterol J"},{"issue":"4","key":"1558_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ibd\/izab099","volume":"28","author":"J Hanzel","year":"2021","unstructured":"Hanzel J, et al. Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study. Inflamm Bowel Dis. 2021;28(4):495\u2013501.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"1558_CR27","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.dld.2022.07.004","volume":"54","author":"L Lontai","year":"2022","unstructured":"Lontai L, et al. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease & #x2013; a prospective, multicentre study. Dig Liver Dis. 2022;54(12):1639\u201345.","journal-title":"Dig Liver Dis"},{"issue":"12","key":"1558_CR28","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.cgh.2018.12.036","volume":"17","author":"A Ilias","year":"2019","unstructured":"Ilias A, et al. Outcomes of patients with inflammatory bowel diseases switched from maintenance therapy with a biosimilar to remicade. Clin Gastroenterol Hepatol. 2019;17(12):2506-2513.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"1558_CR29","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/ecco-jcc\/jjw087","volume":"10","author":"LJT Smits","year":"2016","unstructured":"Smits LJT, et al. Clinical outcomes following a switch from remicade\u00ae to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohn\u2019s and Colitis. 2016;10(11):1287\u201393.","journal-title":"J Crohn's and Colitis"},{"issue":"9","key":"1558_CR30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288393","volume":"18","author":"T Kazama","year":"2023","unstructured":"Kazama T, et al. Long-term effectiveness and safety of infliximab-biosimilar: a multicenter phoenix retrospective cohort study. PLoS ONE. 2023;18(9): e0288393.","journal-title":"PLoS ONE"},{"issue":"11","key":"1558_CR31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40264-018-0684-9","volume":"41","author":"Y Ingrasciotta","year":"2018","unstructured":"Ingrasciotta Y, et al. Safety of biologics, including biosimilars: perspectives on current status and future direction. Drug Safet. 2018;41(11):1013\u201322.","journal-title":"Drug Safet"},{"key":"1558_CR32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","volume":"11","author":"P Rawla","year":"2018","unstructured":"Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res. 2018;11:215\u201326.","journal-title":"J Inflamm Res"},{"key":"1558_CR33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2020.08.008","volume":"156","author":"A Varanko","year":"2020","unstructured":"Varanko A, Saha S, Chilkoti A. Recent trends in protein and peptide-based biomaterials for advanced drug delivery. Adv Drug Deliv Rev. 2020;156:133\u201387.","journal-title":"Adv Drug Deliv Rev"},{"key":"1558_CR34","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113899","volume":"176","author":"M Dur\u00e1n-Lobato","year":"2021","unstructured":"Dur\u00e1n-Lobato M, et al. Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape. Adv Drug Deliv Rev. 2021;176: 113899.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1558_CR35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00439-023-02521-9","volume":"142","author":"D Jans","year":"2023","unstructured":"Jans D, Cleynen I. The genetics of non-monogenic IBD. Hum Genet. 2023;142(5):669\u201382.","journal-title":"Hum Genet"},{"issue":"5","key":"1558_CR36","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1053\/j.gastro.2015.08.001","volume":"149","author":"DP McGovern","year":"2015","unstructured":"McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology. 2015;149(5):1163-1176.e2.","journal-title":"Gastroenterology"},{"key":"1558_CR37","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104892","volume":"159","author":"V Annese","year":"2020","unstructured":"Annese V. Genetics and epigenetics of IBD. Pharmacol Res. 2020;159: 104892.","journal-title":"Pharmacol Res"},{"issue":"7422","key":"1558_CR38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119\u201324.","journal-title":"Nature"},{"issue":"9","key":"1558_CR39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","volume":"47","author":"JZ Liu","year":"2015","unstructured":"Liu JZ, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979\u201386.","journal-title":"Nat Genet"},{"issue":"10","key":"1558_CR40","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamapediatrics.2017.2571","volume":"171","author":"DS Shouval","year":"2017","unstructured":"Shouval DS, Rufo PA. The role of environmental factors in the pathogenesis of inflammatory bowel diseases: a review. JAMA Pediatr. 2017;171(10):999\u20131005.","journal-title":"JAMA Pediatr"},{"issue":"1","key":"1558_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","volume":"11","author":"A Nishida","year":"2018","unstructured":"Nishida A, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1\u201310.","journal-title":"Clin J Gastroenterol"},{"issue":"4","key":"1558_CR42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/00365521.2018.1447597","volume":"53","author":"B Ahluwalia","year":"2018","unstructured":"Ahluwalia B, et al. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018;53(4):379\u201389.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"1558_CR43","volume":"15","author":"MA Muzammil","year":"2023","unstructured":"Muzammil MA, et al. Advancements in inflammatory bowel disease: a narrative review of diagnostics, management, epidemiology, prevalence, patient outcomes, quality of life, and clinical presentation. Cureus. 2023;15(6): e41120.","journal-title":"Cureus"},{"issue":"4","key":"1558_CR44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00054725-199811000-00014","volume":"4","author":"A Kornbluth","year":"1998","unstructured":"Kornbluth A. Infliximab approved for use in crohn\u2019s disease: a report on the fda gi advisory committee conference. Inflamm Bowel Dis. 1998;4(4):328\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"9317","key":"1558_CR45","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, et al. Maintenance infliximab for crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet"},{"issue":"23","key":"1558_CR46","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376.","journal-title":"N Engl J Med"},{"issue":"1","key":"1558_CR47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2796.2011.02344.x","volume":"270","author":"OH Nielsen","year":"2011","unstructured":"Nielsen OH, et al. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270(1):15\u201328.","journal-title":"J Intern Med"},{"issue":"1","key":"1558_CR48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, et al. Adalimumab for maintenance of clinical response and remission in patients with crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132(1):52\u201365.","journal-title":"Gastroenterology"},{"issue":"9","key":"1558_CR49","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232\u20139.","journal-title":"Gut"},{"issue":"1","key":"1558_CR50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85\u201395.","journal-title":"Gastroenterology"},{"issue":"2","key":"1558_CR51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","volume":"2","author":"N Goel","year":"2010","unstructured":"Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137\u201347.","journal-title":"MAbs"},{"issue":"11","key":"1558_CR52","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/apt.14631","volume":"47","author":"MT Tang","year":"2018","unstructured":"Tang MT, et al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-\u03b27 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47(11):1440\u201352.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1558_CR53","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/ecco-jcc\/jjad199","volume":"18","author":"S Vermeire","year":"2023","unstructured":"Vermeire S, et al. Efficacy and safety of the anti-mucosal addressin cell adhesion molecule-1 antibody ontamalimab in patients with moderate-to-severe ulcerative colitis or crohn\u2019s disease. J Crohns Colitis. 2023;18(5):708\u201319.","journal-title":"J Crohns Colitis"},{"issue":"17","key":"1558_CR54","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","volume":"24","author":"SC Park","year":"2018","unstructured":"Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol. 2018;24(17):1868\u201380.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"1558_CR55","first-page":"Cd006097","volume":"8","author":"SM Nelson","year":"2018","unstructured":"Nelson SM, et al. Natalizumab for induction of remission in crohn\u2019s disease. Cochrane Database Syst Rev. 2018;8(8):Cd006097.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1558_CR56","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1517\/14740338.2015.1063612","volume":"14","author":"M Hagan","year":"2015","unstructured":"Hagan M, Cross RK. Safety of vedolizumab in the treatment of Crohn\u2019s disease and ulcerative colitis. Expert Opin Drug Saf. 2015;14(9):1473\u20139.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1558_CR57","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative Colitis. Gastroenterology. 2020;158(3):562-572.e12.","journal-title":"Gastroenterology"},{"issue":"5","key":"1558_CR58","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/MIB.0000000000000396","volume":"21","author":"MH Mosli","year":"2015","unstructured":"Mosli MH, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a cochrane systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(5):1151\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"1558_CR59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","volume":"16","author":"S Vermeire","year":"2022","unstructured":"Vermeire S, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active crohn\u2019s disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022;16(1):27\u201338.","journal-title":"J Crohns Colitis"},{"issue":"23","key":"1558_CR60","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3748\/wjg.v24.i23.2457","volume":"24","author":"ML Scribano","year":"2018","unstructured":"Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol. 2018;24(23):2457\u201367.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"1558_CR61","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/MIB.0000000000000865","volume":"22","author":"N Singh","year":"2016","unstructured":"Singh N, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(9):2121\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"1558_CR62","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/MIB.0000000000000918","volume":"22","author":"MA Conrad","year":"2016","unstructured":"Conrad MA, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425\u201331.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1558_CR63","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/j.gastro.2018.11.035","volume":"156","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn WJ, et al. Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology. 2019;156(4):946-957.e18.","journal-title":"Gastroenterology"},{"issue":"3","key":"1558_CR64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.5217\/ir.2018.00141","volume":"17","author":"T Hibi","year":"2019","unstructured":"Hibi T, et al. Efficacy and safety of abrilumab, an \u03b14\u03b27 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res. 2019;17(3):375\u201386.","journal-title":"Intest Res"},{"issue":"6","key":"1558_CR65","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40259-020-00451-w","volume":"34","author":"A Almradi","year":"2020","unstructured":"Almradi A, et al. Clinical trials of IL-12\/IL-23 inhibitors in inflammatory bowel disease. BioDrugs. 2020;34(6):713\u201321.","journal-title":"BioDrugs"},{"issue":"13","key":"1558_CR66","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314.","journal-title":"N Engl J Med"},{"issue":"4","key":"1558_CR67","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","volume":"155","author":"P Rutgeerts","year":"2018","unstructured":"Rutgeerts P, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with crohn\u2019s disease. Gastroenterology. 2018;155(4):1045\u201358.","journal-title":"Gastroenterology"},{"issue":"36","key":"1558_CR68","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.3748\/wjg.v24.i36.4093","volume":"24","author":"I Aggeletopoulou","year":"2018","unstructured":"Aggeletopoulou I, et al. Interleukin 12\/interleukin 23 pathway: Biological basis and therapeutic effect in patients with crohn\u2019s disease. World J Gastroenterol. 2018;24(36):4093\u2013103.","journal-title":"World J Gastroenterol"},{"key":"1558_CR69","doi-asserted-by":"crossref","unstructured":"McDonald, B.D., E.C. Dyer, and D.T. Rubin 2022, IL-23 Monoclonal Antibodies for IBD: So Many, So Different?. J Crohns Colitis 16(Supplement_2) 42-53.","DOI":"10.1093\/ecco-jcc\/jjac038"},{"key":"1558_CR70","unstructured":"SKYRIZI\u00ae (risankizumab-rzaa). 2024."},{"issue":"10","key":"1558_CR71","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","volume":"3","author":"BG Feagan","year":"2018","unstructured":"Feagan BG, et al. Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3(10):671\u201380.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10080","key":"1558_CR72","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","volume":"389","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699\u2013709.","journal-title":"Lancet"},{"issue":"10340","key":"1558_CR73","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D'Haens","year":"2022","unstructured":"D\u2019Haens G, et al. Risankizumab as induction therapy for crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015\u201330.","journal-title":"Lancet"},{"issue":"11","key":"1558_CR74","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40265-023-01909-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Mirikizumab: first approval. Drugs. 2023;83(11):1045\u201352.","journal-title":"Drugs"},{"issue":"26","key":"1558_CR75","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D'Haens","year":"2023","unstructured":"D\u2019Haens G, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444\u201355.","journal-title":"N Engl J Med"},{"issue":"6","key":"1558_CR76","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","volume":"162","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, et al. Guselkumab for the treatment of crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650-1664.e8.","journal-title":"Gastroenterology"},{"issue":"6","key":"1558_CR77","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","volume":"165","author":"L Peyrin-Biroulet","year":"2023","unstructured":"Peyrin-Biroulet L, et al. Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR Phase 2b induction study. Gastroenterology. 2023;165(6):1443\u201357.","journal-title":"Gastroenterology"},{"issue":"23","key":"1558_CR78","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.3390\/jcm10235660","volume":"10","author":"P Dudek","year":"2021","unstructured":"Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, safety and future perspectives of jak inhibitors in the ibd treatment. J Clin Med. 2021;10(23):5660.","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"1558_CR79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000507782","volume":"101","author":"B Misselwitz","year":"2020","unstructured":"Misselwitz B, et al. Emerging treatment options in inflammatory bowel disease: janus kinases, stem cells, and more. Digestion. 2020;101(Suppl 1):69\u201382.","journal-title":"Digestion"},{"issue":"48","key":"1558_CR80","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.3748\/wjg.v28.i48.6888","volume":"28","author":"YH Xu","year":"2022","unstructured":"Xu YH, Zhu WM, Guo Z. Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease. World J Gastroenterol. 2022;28(48):6888\u201399.","journal-title":"World J Gastroenterol"},{"issue":"10093","key":"1558_CR81","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457\u201368.","journal-title":"Lancet"},{"issue":"8","key":"1558_CR82","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139-2149.e14.","journal-title":"Gastroenterology"},{"issue":"10","key":"1558_CR83","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","volume":"20","author":"G D'Haens","year":"2022","unstructured":"D\u2019Haens G, et al. Upadacitinib was efficacious and well-tolerated over 30 months in patients with crohn\u2019s disease in the CELEST extension study. Clin Gastroenterol Hepatol. 2022;20(10):2337-2346.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10341","key":"1558_CR84","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. The lancet. 2022;399(10341):2113\u201328.","journal-title":"The lancet"},{"issue":"9","key":"1558_CR85","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","volume":"21","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, et al. Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment. Clin Gastroenterol Hepatol. 2023;21(9):2347\u201358.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10066","key":"1558_CR86","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266\u201375.","journal-title":"Lancet"},{"issue":"18","key":"1558_CR87","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1080\/14656566.2021.1967929","volume":"22","author":"C Richez","year":"2021","unstructured":"Richez C, Truchetet ME. Evaluating filgotinib for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2021;22(18):2435\u201344.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"1558_CR88","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ibd\/izab135","volume":"27","author":"S Danese","year":"2021","unstructured":"Danese S, Peyrin-Biroulet L. Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise. Inflamm Bowel Dis. 2021;27(12):2023\u201330.","journal-title":"Inflamm Bowel Dis"},{"key":"1558_CR89","doi-asserted-by":"crossref","unstructured":"Sokic-Milutinovic, A. and T. Milosavljevic, IBD: from conventional immunosuppression to biological therapy. In: Dig Dis, 2023.","DOI":"10.1159\/000535647"},{"issue":"8","key":"1558_CR90","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","volume":"57","author":"JQ Tran","year":"2017","unstructured":"Tran JQ, et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. J Clin Pharmacol. 2017;57(8):988\u201396.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1558_CR91","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","volume":"5","author":"BG Feagan","year":"2020","unstructured":"Feagan BG, et al. Ozanimod induction therapy for patients with moderate to severe crohn\u2019s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5(9):819\u201328.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1558_CR92","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106958","volume":"122","author":"BG Feagan","year":"2022","unstructured":"Feagan BG, et al. Ozanimod as a novel oral small molecule therapy for the treatment of crohn\u2019s disease: The YELLOWSTONE clinical trial program. Contemp Clin Trials. 2022;122: 106958.","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"1558_CR93","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):550\u201361.","journal-title":"Gastroenterology"},{"issue":"10383","key":"1558_CR94","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet. 2023;401(10383):1159\u201371.","journal-title":"The Lancet"},{"key":"1558_CR95","unstructured":"Pfizer. U.S. FDA Approves Pfizer\u2019s VELSIPITY\u2122 for Adults with Moderately to Severely Active Ulcerative Colitis (UC). 2023 [cited 2024; Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-velsipitytm-adults-moderately"},{"issue":"9","key":"1558_CR96","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.14309\/ajg.0000000000002345","volume":"118","author":"O Kahn-Boesel","year":"2023","unstructured":"Kahn-Boesel O, et al. A narrative review of financial burden, distress, and toxicity of inflammatory bowel diseases in the united states. Am J Gastroenterol. 2023;118(9):1545\u201353.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1558_CR97","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/MIB.0000000000001153","volume":"23","author":"A Yadav","year":"2017","unstructured":"Yadav A, et al. Variations in health insurance policies regarding biologic therapy use in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(6):853\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"1558_CR98","unstructured":"FDA. What Are \"Biologics\" Questions and Answers. 2018 [cited 2024; Available from: https:\/\/www.fda.gov\/about-fda\/center-biologics-evaluation-and-research-cber\/what-are-biologics-questions-and-answers."},{"issue":"16","key":"1558_CR99","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.3390\/ijerph17165800","volume":"17","author":"V Halimi","year":"2020","unstructured":"Halimi V, Daci A, Ancevska Netkovska K, Suturkova L, Babar ZUD, Grozdanova A. Clinical and regulatory concerns of biosimilars: a review of literature. Int J Environ Res Pub Health. 2020;17(16):5800.","journal-title":"Int J Environ Res Pub Health"},{"key":"1558_CR100","unstructured":"FDA. Biosimilar and Interchangeable Biologics: More Treatment Choices. 2023 [cited 2024; Available from: https:\/\/www.fda.gov\/consumers\/consumer-updates\/biosimilar-and-interchangeable-biologics-more-treatment-choices."},{"issue":"9_suppl","key":"1558_CR101","doi-asserted-by":"crossref","first-page":"17s","DOI":"10.1200\/JOP.2017.026062","volume":"13","author":"RD Harvey","year":"2017","unstructured":"Harvey RD. Science of biosimilars. J Oncol Pract. 2017;13(9_suppl):17s\u201323s.","journal-title":"J Oncol Pract"},{"key":"1558_CR102","unstructured":"FDA. Biosimilar development, review, and approval. 2022 [cited 2024; Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/review-and-approval."},{"issue":"10","key":"1558_CR103","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.19.02953","volume":"38","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, et al. Understanding the role of comparative clinical studies in the development of oncology biosimilars. J Clin Oncol. 2020;38(10):1070\u201380.","journal-title":"J Clin Oncol"},{"key":"1558_CR104","unstructured":"Pfizer. Let\u2019s see how biosimilars are developed. 2023 [cited 2024; Available from: https:\/\/www.pfizerbiosimilars.com\/biosimilars-development"},{"issue":"6","key":"1558_CR105","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1053\/j.gastro.2010.08.049","volume":"139","author":"BP Willing","year":"2010","unstructured":"Willing BP, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139(6):1844-1854.e1.","journal-title":"Gastroenterology"},{"issue":"4","key":"1558_CR106","first-page":"3","volume":"7","author":"AW Mulcahy","year":"2018","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the united states: initial experience and future potential. Rand Health Q. 2018;7(4):3.","journal-title":"Rand Health Q"},{"issue":"6","key":"1558_CR107","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2672.1991.tb02739.x","volume":"70","author":"J Cummings","year":"1991","unstructured":"Cummings J, Macfarlane G. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol. 1991;70(6):443\u201359.","journal-title":"J Appl Bacteriol"},{"key":"1558_CR108","first-page":"5","volume":"11","author":"JR Tesser","year":"2017","unstructured":"Tesser JR, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017;11:5\u201311.","journal-title":"Biologics"},{"key":"1558_CR109","unstructured":"FDA approves Inflectra, a biosimilar to Remicade. U.S. Food & Drug Administration (FDA). 2016; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-inflectra-biosimilar-remicade"},{"key":"1558_CR110","unstructured":"Aboobacker, S. and A.M. Al Aboud, Infliximab-abda, in StatPearls. 2023, StatPearls Publishing"},{"key":"1558_CR111","unstructured":"Copyright \u00a9 2023, StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Ahmad Al Aboud declares no relevant financial relationships with ineligible companies."},{"key":"1558_CR112","doi-asserted-by":"crossref","unstructured":"Angyal, A. and S. Bhat, Biosimilars in IBD: What Every Clinician Needs to Know. Curr Gastroenterol Rep, 2024.","DOI":"10.1007\/s11894-023-00913-5"},{"issue":"8","key":"1558_CR113","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s10620-021-07114-y","volume":"66","author":"S Bhat","year":"2021","unstructured":"Bhat S, et al. Does similarity breed contempt? A review of the use of biosimilars in inflammatory bowel disease. Dig Dis Sci. 2021;66(8):2513\u201332.","journal-title":"Dig Dis Sci"},{"issue":"10086","key":"1558_CR114","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. The Lancet. 2017;389(10086):2304\u201316.","journal-title":"The Lancet"},{"issue":"6","key":"1558_CR115","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/joim.12880","volume":"285","author":"GL Goll","year":"2019","unstructured":"Goll GL, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653\u201369.","journal-title":"J Intern Med"},{"key":"1558_CR116","unstructured":"Celltrion Healthcare. Celltrion USA Announces U.S. FDA Approval of Zymfentra, the first and only subcutaneous infliximab, for the treatment of people with inflammatory bowel disease. . 2023 October 23, 2023; Available from: https:\/\/www.celltrionhealthcare.com\/board\/en_newslist\/109."},{"issue":"Supplement_1","key":"1558_CR117","doi-asserted-by":"crossref","first-page":"i623","DOI":"10.1093\/ecco-jcc\/jjac190.0622","volume":"17","author":"BE Sands","year":"2023","unstructured":"Sands BE, et al. P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: a phase 3, randomized, placebo-controlled study: results of the LIBERTY-UC study. J Crohn\u2019s Colitis. 2023;17(Supplement_1):i623\u20134.","journal-title":"J Crohn's Colitis"},{"issue":"Supplement_1","key":"1558_CR118","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ecco-jcc\/jjac190.0126","volume":"17","author":"JF Colombel","year":"2023","unstructured":"Colombel JF, et al. DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn\u2019s disease: a phase 3, randomised, placebo-controlled study (LIBERTY-CD). J Crohn\u2019s Colitis. 2023;17(Supplement_1):161\u20132.","journal-title":"J Crohn's Colitis"},{"issue":"7","key":"1558_CR119","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340\u201353.","journal-title":"Gastroenterology"},{"issue":"5","key":"1558_CR120","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","volume":"60","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial. Rheumatology. 2021;60(5):2277\u201387.","journal-title":"Rheumatology"},{"issue":"7","key":"1558_CR121","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102849","volume":"20","author":"F D'Amico","year":"2021","unstructured":"D\u2019Amico F, et al. Biobetters in patients with immune-mediated inflammatory disorders: an international delphi consensus. Autoimmun Rev. 2021;20(7): 102849.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1558_CR122","doi-asserted-by":"crossref","first-page":"otaa093","DOI":"10.1093\/crocol\/otaa093","volume":"3","author":"S Bhat","year":"2021","unstructured":"Bhat S, Qazi T. Switching from infliximab to biosimilar in inflammatory bowel disease: a review of existing literature and best practices. Crohn\u2019s & Colitis 360. 2021;3(1):otaa093.","journal-title":"Crohn's & Colitis 360"},{"issue":"18","key":"1558_CR123","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/ajhp\/zxad120","volume":"80","author":"S Cisek","year":"2023","unstructured":"Cisek S, et al. Preparing for the market entry of adalimumab biosimilars in the US in 2023: a primer for specialty pharmacists. Am J Health Syst Pharm. 2023;80(18):1223\u201333.","journal-title":"Am J Health Syst Pharm"},{"key":"1558_CR124","doi-asserted-by":"crossref","first-page":"1151764","DOI":"10.3389\/fphar.2023.1151764","volume":"14","author":"E Car","year":"2023","unstructured":"Car E, et al. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front pharmacol. 2023;14:1151764.","journal-title":"Front pharmacol"},{"issue":"10","key":"1558_CR125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2468-1253(21)00252-1","volume":"6","author":"S Hanauer","year":"2021","unstructured":"Hanauer S, et al. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced crohn\u2019s disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gastroenterol Hepatolo. 2021;6(10):816\u201325.","journal-title":"Lancet Gastroenterol Hepatolo"},{"issue":"1","key":"1558_CR126","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ibd\/izab027","volume":"28","author":"G Tapete","year":"2021","unstructured":"Tapete G, et al. Effectiveness and safety of nonmedical switch from adalimumab originator to sb5 biosimilar in patients with inflammatory bowel diseases: twelve-month follow-up from the TABLET registry. Inflamm Bowel Dis. 2021;28(1):62\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1558_CR127","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ibd\/izac092","volume":"29","author":"A Tursi","year":"2022","unstructured":"Tursi A, et al. Comparison of performances of adalimumab biosimilars SB5, ABP501, GP2017, and MSB11022 in treating patients with inflammatory bowel diseases: a real-life, multicenter. Observat Study Inflamm Bowel Dis. 2022;29(3):376\u201383.","journal-title":"Observat Study Inflamm Bowel Dis"},{"issue":"12","key":"1558_CR128","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/ecco-jcc\/jjab100","volume":"15","author":"L Derikx","year":"2021","unstructured":"Derikx L, et al. Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-na\u00efve SB5 observational cohorts. J Crohns Colitis. 2021;15(12):2011\u201321.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"1558_CR129","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/jcm13020556","volume":"13","author":"MC Fern\u00e1ndez-Cano","year":"2024","unstructured":"Fern\u00e1ndez-Cano MC, et al. Adalimumab persistence and its biosimilar in inflammatory bowel disease: a real-world study. J Clin Med. 2024;13(2):556.","journal-title":"J Clin Med"},{"issue":"21","key":"1558_CR130","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.3390\/jcm12216839","volume":"12","author":"M Vernero","year":"2023","unstructured":"Vernero M, et al. Efficacy and safety of adalimumab biosimilar GP2017 in patients with inflammatory bowel disease. J Clin Med. 2023;12(21):6839.","journal-title":"J Clin Med"},{"key":"1558_CR131","doi-asserted-by":"crossref","first-page":"1259183","DOI":"10.3389\/fphar.2023.1259183","volume":"14","author":"F Wang","year":"2023","unstructured":"Wang F, et al. Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study. Front Pharmacol. 2023;14:1259183.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1558_CR132","doi-asserted-by":"crossref","first-page":"10368","DOI":"10.1038\/s41598-021-89790-4","volume":"11","author":"L Cingolani","year":"2021","unstructured":"Cingolani L, et al. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. Sci Rep. 2021;11(1):10368.","journal-title":"Sci Rep"},{"issue":"7","key":"1558_CR133","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/ecco-jcc\/jjaa001","volume":"14","author":"M Lukas","year":"2020","unstructured":"Lukas M, et al. Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: short-term experience from a single tertiary clinical centre. J Crohns Colitis. 2020;14(7):915\u20139.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1558_CR134","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12325-023-02712-w","volume":"41","author":"R Jin","year":"2024","unstructured":"Jin R, et al. Real-world experience of adalimumab biosimilar (ABP 501) use in patients with inflammatory bowel disease in Europe. Adv Ther. 2024;41(1):331\u201348.","journal-title":"Adv Ther"},{"issue":"10","key":"1558_CR135","first-page":"952","volume":"24","author":"JS Odinet","year":"2018","unstructured":"Odinet JS, et al. The biosimilar nocebo effect? a systematic review of double-blinded versus open-label studies. J Manag Care Spec Pharm. 2018;24(10):952\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"1558_CR136","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40257-022-00708-w","volume":"23","author":"A Menter","year":"2022","unstructured":"Menter A, et al. Switching between adalimumab reference product and bi 695501 in patients with chronic plaque psoriasis (VOLTAIRE-X): a randomized controlled trial. Am J Clin Dermatol. 2022;23(5):719\u201328.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1558_CR137","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S2665-9913(23)00161-3","volume":"5","author":"RM Fleischmann","year":"2023","unstructured":"Fleischmann RM, et al. Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study. Lancet Rheumatol. 2023;5(9):e532\u201341.","journal-title":"Lancet Rheumatol"},{"key":"1558_CR138","unstructured":"Pharmacy Practice Newes. A Review of Newly Available Humira Biosimilars for Pharmacists.. November 2023 [cited 2024; Available from: https:\/\/www.pharmacypracticenews.com\/Review-Articles\/Article\/12-23\/A-Review-of-Newly-Available-Humira-Biosimilars-for-Pharmacists\/72110."},{"issue":"1","key":"1558_CR139","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40744-020-00256-x","volume":"8","author":"M Bergman","year":"2021","unstructured":"Bergman M, et al. Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the united states. Rheumatol Ther. 2021;8(1):109\u201318.","journal-title":"Rheumatol Ther"},{"key":"1558_CR140","unstructured":"Humira (adalimumab) [package insert]. . 2002."},{"key":"1558_CR141","doi-asserted-by":"publisher","unstructured":"Food and Drug Administration. FDA approves interchangeable biosimilar for multiple inflammatory diseases. 2023 October 31, 2023.; Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s11894-023-00913-5#citeas","DOI":"10.1007\/s11894-023-00913-5#citeas"},{"key":"1558_CR142","unstructured":"2023 Biosimilars Report. Cardinal Health. 2023 [cited 2024; Available from: https:\/\/www.cardinalhealth.com\/en\/product-solutions\/pharmaceutical-products\/biosimilars\/biosimilars-report.html."},{"issue":"5","key":"1558_CR143","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.clinthera.2017.03.014","volume":"39","author":"C Blandizzi","year":"2017","unstructured":"Blandizzi C, Meroni PL, Lapadula G. Comparing originator biologics and biosimilars: a review of the relevant issues. Clin Ther. 2017;39(5):1026\u201339.","journal-title":"Clin Ther"},{"issue":"7","key":"1558_CR144","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.autrev.2015.02.007","volume":"14","author":"M Deehan","year":"2015","unstructured":"Deehan M, et al. Managing unwanted immunogenicity of biologicals. Autoimmun Rev. 2015;14(7):569\u201374.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1558_CR145","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. Aaps j. 2012;14(2):296\u2013302.","journal-title":"Aaps j"},{"issue":"2","key":"1558_CR146","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165\u201378.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1558_CR147","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda G, et al. Loss of response to Anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1): e135.","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"1558_CR148","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1517\/17425250802525496","volume":"4","author":"J Descotes","year":"2008","unstructured":"Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol. 2008;4(12):1537\u201349.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"1558_CR149","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, et al. Influence of immunogenicity on the long-term efficacy of infliximab in crohn\u2019s disease. N Engl J Med. 2003;348(7):601\u20138.","journal-title":"N Engl J Med"},{"issue":"11","key":"1558_CR150","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","volume":"68","author":"TR Radstake","year":"2009","unstructured":"Radstake TR, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1739\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1558_CR151","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4155\/bio.13.6","volume":"5","author":"P Chamberlain","year":"2013","unstructured":"Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis. 2013;5(5):561\u201374.","journal-title":"Bioanalysis"},{"issue":"2","key":"1558_CR152","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrgastro.2009.221","volume":"7","author":"S de Silva","year":"2010","unstructured":"de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7(2):93\u2013101.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1558_CR153","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/nyas.14522","volume":"1491","author":"HN Kang","year":"2021","unstructured":"Kang HN, et al. Regulatory challenges with biosimilars: an update from 20 countries. Ann N Y Acad Sci. 2021;1491(1):42\u201359.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"1558_CR154","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102107","volume":"47","author":"A Bozon","year":"2023","unstructured":"Bozon A, et al. Risk of infection in elderly patients with inflammatory bowel disease under biologics: a prospective, multicenter, observational, one-year follow-up comparative study. Clin Res Hepatol Gastroenterol. 2023;47(5): 102107.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"1558_CR155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","volume":"155","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner J, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337-346.e10.","journal-title":"Gastroenterology"},{"issue":"3","key":"1558_CR156","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3892\/etm.2021.10381","volume":"22","author":"I Pintea","year":"2021","unstructured":"Pintea I, et al. Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review). Exp Ther Med. 2021;22(3):949.","journal-title":"Exp Ther Med"},{"key":"1558_CR157","doi-asserted-by":"crossref","first-page":"1219735","DOI":"10.3389\/falgy.2023.1219735","volume":"4","author":"A Sitek","year":"2023","unstructured":"Sitek A, Chiarella SE, Pongdee T. Hypersensitivity reactions to biologics used in the treatment of allergic diseases: clinical features, diagnosis and management. Front allergy. 2023;4:1219735.","journal-title":"Front allergy"},{"issue":"1","key":"1558_CR158","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/all.14984","volume":"77","author":"S Bavbek","year":"2022","unstructured":"Bavbek S, et al. Hypersensitivity reactions to biologicals: An EAACI position paper. Allergy. 2022;77(1):39\u201354.","journal-title":"Allergy"},{"issue":"2","key":"1558_CR159","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ecco-jcc\/jjv193","volume":"10","author":"JC Wilson","year":"2015","unstructured":"Wilson JC, et al. Inflammatory bowel disease and the risk of autoimmune diseases. J Crohns Colitis. 2015;10(2):186\u201393.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"1558_CR160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.31138\/mjr.32.2.96","volume":"32","author":"AA Drosos","year":"2021","unstructured":"Drosos AA, et al. Biologic therapies and autoimmune phenomena. Mediterr J Rheumatol. 2021;32(2):96\u2013103.","journal-title":"Mediterr J Rheumatol"},{"key":"1558_CR161","unstructured":"Remicade (Infliximab) [package insert]. 2016."},{"key":"1558_CR162","unstructured":"Inflectra (Infliximab-dyyb) [package insert]. 2016."},{"key":"1558_CR163","unstructured":"Renflexis (Infliximab-abda) [package insert]. 2017."},{"key":"1558_CR164","unstructured":"Ixifi (infliximab-qbtx) [[package insert]. . 2017."},{"key":"1558_CR165","unstructured":"Avsola (infliximab-axxq) [package insert]. . 2019."},{"key":"1558_CR166","unstructured":"Amjevita (Adalimumab -atto) [package insert]. 2016."},{"key":"1558_CR167","unstructured":"Cyltezo (Adalimumab-adbm) [package insert]. 2017."},{"key":"1558_CR168","unstructured":"Hyrimoz (adalimumab-adaz) [package insert]. 2018."},{"key":"1558_CR169","unstructured":"Hadlima (adalimumab-bwwd) [package insert]. 2019"},{"key":"1558_CR170","unstructured":"Abrilada (adalimumab-afzb) [package insert]. 2019"},{"key":"1558_CR171","unstructured":"Hulio (adalimumab-fkjp) [package insert]. 2020."},{"key":"1558_CR172","unstructured":"Yusimry (adalimumab-aqvh) [package insert]. 2021."},{"key":"1558_CR173","unstructured":"Idacio (adalimumab-aacf) [package insert]. 2022."},{"key":"1558_CR174","unstructured":"Yuflyma (adalimumab-aaty) [package insert]. 2023."},{"key":"1558_CR175","unstructured":"Stelara (ustekinumab) [package insert]. 2009."},{"key":"1558_CR176","unstructured":"Wezlana (ustekinumab-auub) [package insert]. 2023."},{"issue":"4","key":"1558_CR177","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.apsb.2020.12.018","volume":"11","author":"Q Xiao","year":"2021","unstructured":"Xiao Q, et al. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B. 2021;11(4):941\u201360.","journal-title":"Acta Pharm Sin B"},{"key":"1558_CR178","first-page":"138","volume":"34","author":"G Han","year":"2024","unstructured":"Han G, et al. Oral TNF-\u03b1 siRNA delivery via milk-derived exosomes for effective treatment of inflammatory bowel disease. Bioact Mater. 2024;34:138\u201349.","journal-title":"Bioact Mater"},{"key":"1558_CR179","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2013.10.001","volume":"71","author":"C Lautenschl\u00e4ger","year":"2014","unstructured":"Lautenschl\u00e4ger C, et al. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev. 2014;71:58\u201376.","journal-title":"Adv Drug Deliv Rev"},{"key":"1558_CR180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.nantod.2017.08.006","volume":"16","author":"S Zhang","year":"2017","unstructured":"Zhang S, Langer R, Traverso G. Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. Nano Today. 2017;16:82\u201396.","journal-title":"Nano Today"},{"key":"1558_CR181","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.2147\/IJN.S210315","volume":"14","author":"C Yang","year":"2019","unstructured":"Yang C, Merlin D. Nanoparticle-mediated drug delivery systems for the treatment of IBD: current perspectives. Int J Nanomedicine. 2019;14:8875\u201389.","journal-title":"Int J Nanomedicine"},{"key":"1558_CR182","volume":"58","author":"AM Helmy","year":"2020","unstructured":"Helmy AM, et al. High-Payload chitosan microparticles for the colonic delivery of quercetin: development and in-vivo evaluation in a rabbit colitis model. J Drug Deliv Sci Technol. 2020;58: 101832.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1558_CR183","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejps.2017.08.025","volume":"109","author":"AM Helmy","year":"2017","unstructured":"Helmy AM, et al. Development and in vivo evaluation of chitosan beads for the colonic delivery of azathioprine for treatment of inflammatory bowel disease. Eur J Pharm Sci. 2017;109:269\u201379.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"1558_CR184","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1007\/s13346-023-01363-2","volume":"13","author":"SS Seoudi","year":"2023","unstructured":"Seoudi SS, et al. Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression. Drug Deliv Transl Res. 2023;13(11):2930\u201347.","journal-title":"Drug Deliv Transl Res"},{"key":"1558_CR185","volume":"9","author":"W Zhang","year":"2021","unstructured":"Zhang W, Michalowski CB, Beloqui A. Oral delivery of biologics in inflammatory bowel disease treatment. Front Bioeng Biotechnol. 2021;9: 675194.","journal-title":"Front Bioeng Biotechnol"},{"issue":"19","key":"1558_CR186","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.2217\/nnm-2019-0191","volume":"14","author":"R Nunes","year":"2019","unstructured":"Nunes R, Neves JD, Sarmento B. Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges. Nanomedicine (Lond). 2019;14(19):2631\u201344.","journal-title":"Nanomedicine (Lond)"},{"issue":"18","key":"1558_CR187","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3748\/wjg.v28.i18.1922","volume":"28","author":"F Yasmin","year":"2022","unstructured":"Yasmin F, et al. Novel drug delivery systems for inflammatory bowel disease. World J Gastroenterol. 2022;28(18):1922\u201333.","journal-title":"World J Gastroenterol"},{"key":"1558_CR188","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jconrel.2023.07.039","volume":"361","author":"B Lahooti","year":"2023","unstructured":"Lahooti B, et al. Targeting endothelial permeability in the EPR effect. J Control Release. 2023;361:212\u201335.","journal-title":"J Control Release"},{"key":"1558_CR189","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2147\/DDDT.S390274","volume":"17","author":"K Dong","year":"2023","unstructured":"Dong K, et al. Mucoadhesive nanoparticles enhance the therapeutic effect of dexamethasone on experimental ulcerative colitis by the local administration as an enema. Drug Des Devel Ther. 2023;17:191\u2013207.","journal-title":"Drug Des Devel Ther"},{"issue":"Pt 1","key":"1558_CR190","volume":"254","author":"S Zhao","year":"2024","unstructured":"Zhao S, et al. Mucoadhesive and thermosensitive bletilla striata polysaccharide\/chitosan hydrogel loaded nanoparticles for rectal drug delivery in ulcerative colitis. Int J Biol Macromol. 2024;254(Pt 1): 127761.","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"1558_CR191","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1023\/A:1011032328064","volume":"18","author":"A Lamprecht","year":"2001","unstructured":"Lamprecht A, Sch\u00e4fer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001;18(6):788\u201393.","journal-title":"Pharm Res"},{"issue":"2","key":"1558_CR192","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2012.10.019","volume":"165","author":"C Schmidt","year":"2013","unstructured":"Schmidt C, et al. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J Control Release. 2013;165(2):139\u201345.","journal-title":"J Control Release"},{"key":"1558_CR193","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.actbio.2021.12.015","volume":"140","author":"N Shrestha","year":"2022","unstructured":"Shrestha N, et al. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. Acta Biomater. 2022;140:561\u201372.","journal-title":"Acta Biomater"},{"issue":"3 Pt A","key":"1558_CR194","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ejpb.2013.09.016","volume":"85","author":"C Lautenschl\u00e4ger","year":"2013","unstructured":"Lautenschl\u00e4ger C, et al. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J Pharm Biopharm. 2013;85(3 Pt A):578\u201386.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"1558_CR195","doi-asserted-by":"crossref","first-page":"20175","DOI":"10.1038\/s41598-023-47445-6","volume":"13","author":"R Schmid","year":"2023","unstructured":"Schmid R, et al. Surface functionalization affects the retention and bio-distribution of orally administered mesoporous silica nanoparticles in a colitis mouse model. Sci Rep. 2023;13(1):20175.","journal-title":"Sci Rep"},{"key":"1558_CR196","volume":"129","author":"X Li","year":"2020","unstructured":"Li X, et al. Site-specific targeted drug delivery systems for the treatment of inflammatory bowel disease. Biomed Pharmacother. 2020;129: 110486.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1558_CR197","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1208\/s12249-023-02568-x","volume":"24","author":"H Maleki","year":"2023","unstructured":"Maleki H, et al. Achillea wilhelmsii-incorporated chitosan@eudragit nanoparticles intended for enhanced ulcerative colitis treatment. AAPS PharmSciTech. 2023;24(5):112.","journal-title":"AAPS PharmSciTech"},{"issue":"Pt 1","key":"1558_CR198","volume":"254","author":"Y Tao","year":"2024","unstructured":"Tao Y, et al. Chitosan-coated artesunate protects against ulcerative colitis via STAT6-mediated macrophage M2 polarization and intestinal barrier protection. Int J Biol Macromol. 2024;254(Pt 1): 127680.","journal-title":"Int J Biol Macromol"},{"key":"1558_CR199","volume":"219","author":"Y Tao","year":"2022","unstructured":"Tao Y, et al. Oral delivery of chitosan-coated PLGA nanoemulsion loaded with artesunate alleviates ulcerative colitis in mice. Colloids Surf B Biointerfaces. 2022;219: 112824.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1558_CR200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113409","volume":"153","author":"M Nasr","year":"2022","unstructured":"Nasr M, et al. Canagliflozin-loaded chitosan-hyaluronic acid microspheres modulate AMPK\/NF-\u03baB\/NLRP3 axis: a new paradigm in the rectal therapy of ulcerative colitis. Biomed Pharmacother. 2022;153: 113409.","journal-title":"Biomed Pharmacother"},{"key":"1558_CR201","volume":"254","author":"W Niu","year":"2021","unstructured":"Niu W, et al. Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: a review. Carbohydr Polym. 2021;254: 117189.","journal-title":"Carbohydr Polym"},{"key":"1558_CR202","volume":"236","author":"L Xu","year":"2024","unstructured":"Xu L, et al. Telmisartan loading thermosensitive hydrogel repairs gut epithelial barrier for alleviating inflammatory bowel disease. Colloids Surf B Biointerfaces. 2024;236: 113799.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"10","key":"1558_CR203","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1007\/s13346-023-01317-8","volume":"13","author":"C Xiao","year":"2023","unstructured":"Xiao C, et al. A topical thermosensitive hydrogel system with cyclosporine A PEG-PCL micelles alleviates ulcerative colitis induced by TNBS in mice. Drug Deliv Transl Res. 2023;13(10):2447\u201362.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"1558_CR204","volume":"15","author":"IM Ibrahim","year":"2023","unstructured":"Ibrahim IM. Advances in polysaccharide-based oral colon-targeted delivery systems: the journey so far and the road ahead. Cureus. 2023;15(1): e33636.","journal-title":"Cureus"},{"key":"1558_CR205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119070","volume":"577","author":"HH Gadalla","year":"2020","unstructured":"Gadalla HH, et al. Colon-targeting of progesterone using hybrid polymeric microspheres improves its bioavailability and in vivo biological efficacy. Int J Pharm. 2020;577: 119070.","journal-title":"Int J Pharm"},{"issue":"4","key":"1558_CR206","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.48.4.571","volume":"48","author":"SG Nugent","year":"2001","unstructured":"Nugent SG, et al. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571\u20137.","journal-title":"Gut"},{"issue":"1","key":"1558_CR207","doi-asserted-by":"crossref","first-page":"2219427","DOI":"10.1080\/10717544.2023.2219427","volume":"30","author":"M Chen","year":"2023","unstructured":"Chen M, et al. Responsive nanosystems for targeted therapy of ulcerative colitis: current practices and future perspectives. Drug Deliv. 2023;30(1):2219427.","journal-title":"Drug Deliv"},{"issue":"1","key":"1558_CR208","doi-asserted-by":"crossref","DOI":"10.1002\/bip.23336","volume":"111","author":"S Bertoni","year":"2020","unstructured":"Bertoni S, et al. Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting. Biopolymers. 2020;111(1): e23336.","journal-title":"Biopolymers"},{"issue":"2","key":"1558_CR209","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s13346-018-0512-x","volume":"9","author":"M Sohail","year":"2019","unstructured":"Sohail M, et al. Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects. Drug Deliv Transl Res. 2019;9(2):595\u2013614.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"1558_CR210","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12272-020-01219-0","volume":"43","author":"M Naeem","year":"2020","unstructured":"Naeem M, et al. Advances in colon-targeted nano-drug delivery systems: challenges and solutions. Arch Pharm Res. 2020;43(1):153\u201369.","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1558_CR211","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41563-019-0462-9","volume":"19","author":"Y Lee","year":"2020","unstructured":"Lee Y, et al. Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater. 2020;19(1):118\u201326.","journal-title":"Nat Mater"},{"key":"1558_CR212","doi-asserted-by":"crossref","first-page":"4535194","DOI":"10.1155\/2017\/4535194","volume":"2017","author":"T Tian","year":"2017","unstructured":"Tian T, Wang Z, Zhang J. Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies. Oxid Med Cell Longev. 2017;2017:4535194.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"1558_CR213","doi-asserted-by":"crossref","first-page":"2031694","DOI":"10.1080\/19490976.2022.2031694","volume":"14","author":"A Froidurot","year":"2022","unstructured":"Froidurot A, Julliand V. Cellulolytic bacteria in the large intestine of mammals. Gut Microbes. 2022;14(1):2031694.","journal-title":"Gut Microbes"},{"issue":"1","key":"1558_CR214","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12951-023-01889-0","volume":"21","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, et al. Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment. J Nanobiotechnology. 2023;21(1):145.","journal-title":"J Nanobiotechnology"},{"issue":"6","key":"1558_CR215","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4110\/in.2016.16.6.337","volume":"16","author":"YS Yi","year":"2016","unstructured":"Yi YS. Folate receptor-targeted diagnostics and therapeutics for inflammatory diseases. Immune Netw. 2016;16(6):337\u201343.","journal-title":"Immune Netw"},{"issue":"1","key":"1558_CR216","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1038\/s41467-018-06103-6","volume":"9","author":"T Zuo","year":"2018","unstructured":"Zuo T, et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in clostridium difficile infection. Nat Commun. 2018;9(1):3663.","journal-title":"Nat Commun"},{"key":"1558_CR217","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213735","volume":"157","author":"ME Rabeh","year":"2024","unstructured":"Rabeh ME, et al. Dual stimuli-responsive delivery system for self-regulated colon-targeted delivery of poorly water-soluble drugs. Biomater Adv. 2024;157: 213735.","journal-title":"Biomater Adv"},{"issue":"5","key":"1558_CR218","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ymthe.2023.02.017","volume":"31","author":"X Yan","year":"2023","unstructured":"Yan X, et al. Reactive oxygen species-responsive nanocarrier ameliorates murine colitis by intervening colonic innate and adaptive immune responses. Mol Ther. 2023;31(5):1383\u2013401.","journal-title":"Mol Ther"},{"issue":"1","key":"1558_CR219","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/pharmaceutics13010018","volume":"13","author":"R New","year":"2020","unstructured":"New R. Oral delivery of biologics via the intestine. Pharmaceutics. 2020;13(1):18.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1558_CR220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2018.183","volume":"18","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2019;18(1):19\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1558_CR221","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12951-021-01090-1","volume":"19","author":"P Eder","year":"2021","unstructured":"Eder P, et al. How could nanobiotechnology improve treatment outcomes of anti-TNF-\u03b1 therapy in inflammatory bowel disease? Current knowledge, future directions. J Nanobiotechnology. 2021;19(1):346.","journal-title":"J Nanobiotechnology"},{"issue":"4","key":"1558_CR222","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1586\/eci.10.30","volume":"6","author":"A Dahan","year":"2010","unstructured":"Dahan A, Amidon GL, Zimmermann EM. Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update. Expert Rev Clin Immunol. 2010;6(4):543\u201350.","journal-title":"Expert Rev Clin Immunol"},{"key":"1558_CR223","volume":"273","author":"X Li","year":"2021","unstructured":"Li X, et al. Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease. Carbohydr Polym. 2021;273: 118556.","journal-title":"Carbohydr Polym"},{"key":"1558_CR224","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106379","volume":"183","author":"LJ Mohan","year":"2023","unstructured":"Mohan LJ, et al. Oral infliximab nanomedicines for targeted treatment of inflammatory bowel diseases. Eur J Pharm Sci. 2023;183: 106379.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"1558_CR225","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbamem.2008.08.027","volume":"1788","author":"CT Capaldo","year":"2009","unstructured":"Capaldo CT, Nusrat A. Cytokine regulation of tight junctions. Biochim Biophys Acta. 2009;1788(4):864\u201371.","journal-title":"Biochim Biophys Acta"},{"issue":"23","key":"1558_CR226","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.7150\/thno.47601","volume":"10","author":"X Wang","year":"2020","unstructured":"Wang X, et al. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Theranostics. 2020;10(23):10808\u201322.","journal-title":"Theranostics"},{"issue":"2","key":"1558_CR227","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/pharmaceutics14020352","volume":"14","author":"M Ries","year":"2022","unstructured":"Ries M, et al. Adalimumab decorated nanoparticles enhance antibody stability and therapeutic outcome in epithelial colitis targeting. Pharmaceutics. 2022;14(2):352.","journal-title":"Pharmaceutics"},{"issue":"12","key":"1558_CR228","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1021\/acs.molpharmaceut.2c00222","volume":"19","author":"OA Abed","year":"2022","unstructured":"Abed OA, et al. Emerging nanotechnologies and microbiome engineering for the treatment of inflammatory bowel disease. Mol Pharm. 2022;19(12):4393\u2013410.","journal-title":"Mol Pharm"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01558-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:54:01Z","timestamp":1764917641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01558-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":228,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1558"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01558-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"107"}}